202 related articles for article (PubMed ID: 33070953)
1. [Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].
Billaud A; Chevalier LM; Campone M; Morel A; Bigot F
Bull Cancer; 2020 Nov; 107(11):1161-1170. PubMed ID: 33070953
[TBL] [Abstract][Full Text] [Related]
2. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
3. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
4. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
6. The challenges of tumor genetic diversity.
Mroz EA; Rocco JW
Cancer; 2017 May; 123(6):917-927. PubMed ID: 27861749
[TBL] [Abstract][Full Text] [Related]
7. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
8. [The breakthrough of personalized medicine, new hopes and new challenges].
Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
[TBL] [Abstract][Full Text] [Related]
9. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
10. Session 2: Mutational discordance: the big challenge in personalized treatments - any solutions?
Siddiqui M; Chand M; Eng C; Mehdizadeh A; Mirnezami A; Brown G
Colorectal Dis; 2018 May; 20 Suppl 1():49-51. PubMed ID: 29878676
[TBL] [Abstract][Full Text] [Related]
11. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
12. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M
Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675
[TBL] [Abstract][Full Text] [Related]
14. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
15. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R; Chan TA
Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
[TBL] [Abstract][Full Text] [Related]
16. Overcoming implementation challenges of personalized cancer therapy.
Meric-Bernstam F; Mills GB
Nat Rev Clin Oncol; 2012 Sep; 9(9):542-8. PubMed ID: 22850751
[TBL] [Abstract][Full Text] [Related]
17. The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.
Lin VTG; Yang ES
J Natl Cancer Inst; 2019 Oct; 111(10):1016-1022. PubMed ID: 31165154
[TBL] [Abstract][Full Text] [Related]
18. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
19. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
